Prohibitin targeting peptide 1

Drug Profile

Prohibitin targeting peptide 1

Alternative Names: Adipotide; Prohibitin-TP01

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Ablaris Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Class Obesity therapies; Peptides; Peptidomimetics
  • Mechanism of Action Apoptosis stimulants; Prohibitin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Obesity in USA (SC, Injection)
  • 04 Jan 2012 FDA approves IND application for prohibitin targeting peptide 1 in Obesity
  • 21 Dec 2010 Preclinical trials in Obesity in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top